Trial Profile
An Open Label Extension Study to Evaluate the Safety, Tolerability and Pharmacokinetics of STX209 in Subjects With Autism Spectrum Disorders [EXTENSION OF 700041825]
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 14 Aug 2013
Price :
$35
*
At a glance
- Drugs Arbaclofen (Primary)
- Indications Irritability; Pervasive child development disorders
- Focus Therapeutic Use
- 14 Aug 2013 New trial record